Core Insights - Alcon reported revenue of $2.58 billion for Q2 2025, a year-over-year increase of 3.8% and an EPS of $0.76, up from $0.74 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $2.61 billion by 1.29%, while the EPS exceeded the consensus estimate of $0.71 by 7.04% [1] Financial Performance Metrics - Alcon's stock has returned +1.1% over the past month, underperforming the Zacks S&P 500 composite's +2.5% change [3] - The company holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3] Regional Sales Performance - International net sales were $1.42 billion, slightly below the estimated $1.45 billion, reflecting a year-over-year increase of +5.7% [4] - U.S. net sales reached $1.16 billion, compared to the estimated $1.18 billion, marking a +1.7% year-over-year change [4] Segment Sales Performance - Total Surgical net sales were $1.46 billion, below the estimated $1.48 billion, with a year-over-year increase of +2.3% [4] - Total Vision Care net sales were $1.12 billion, slightly below the estimated $1.13 billion, showing a +6% year-over-year change [4] - Total Surgical Consumables sales were $777 million, compared to the average estimate of $786.91 million, reflecting a +5.6% year-over-year change [4] - Total Surgical Equipment/Other sales were $222 million, below the estimated $232.7 million, with a -0.5% year-over-year change [4] - Total Vision Care Contact Lenses sales were $692 million, exceeding the estimated $682.51 million, with an +8.8% year-over-year change [4] - Total Vision Care Ocular Health sales were $430 million, below the estimated $446.4 million, reflecting a +1.7% year-over-year change [4] - Total Surgical Implantables sales were $456 million, slightly below the estimated $464.21 million, with a -1.7% year-over-year change [4] - Other revenues were reported at $19 million, exceeding the estimated $17.22 million, with a significant +35.7% year-over-year change [4]